Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Attenuation of Ischemia-Reperfusion Injury and Improvement of Survival in Recipients of Steatotic Rat Livers Using CD47 Monoclonal Antibody.

Xiao Z, Banan B, Xu M, Jia J, Manning PT, Hiebsch RR, Gunasekaran M, Upadhya GA, Frazier WA, Mohanakumar T, Lin Y, Chapman WC.

Transplantation. 2016 Jul;100(7):1480-9. doi: 10.1097/TP.0000000000001186.

PMID:
27331362
2.

CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.

Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM.

Nat Med. 2015 Oct;21(10):1209-15. doi: 10.1038/nm.3931. Epub 2015 Aug 31.

3.

Phosphorylation of the BNIP3 C-Terminus Inhibits Mitochondrial Damage and Cell Death without Blocking Autophagy.

Liu KE, Frazier WA.

PLoS One. 2015 Jun 23;10(6):e0129667. doi: 10.1371/journal.pone.0129667. eCollection 2015.

4.

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma.

Xiao Z, Chung H, Banan B, Manning PT, Ott KC, Lin S, Capoccia BJ, Subramanian V, Hiebsch RR, Upadhya GA, Mohanakumar T, Frazier WA, Lin Y, Chapman WC.

Cancer Lett. 2015 May 1;360(2):302-9. doi: 10.1016/j.canlet.2015.02.036. Epub 2015 Feb 23.

5.

CD47 blockade reduces ischemia/reperfusion injury and improves survival in a rat liver transplantation model.

Xiao ZY, Banan B, Jia J, Manning PT, Hiebsch RR, Gunasekaran M, Upadhya GA, Frazier WA, Mohanakumar T, Lin Y, Chapman WC.

Liver Transpl. 2015 Apr;21(4):468-477. doi: 10.1002/lt.24059. Epub 2015 Jan 29.

6.

CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model.

Lin Y, Manning PT, Jia J, Gaut JP, Xiao Z, Capoccia BJ, Chen CC, Hiebsch RR, Upadhya G, Mohanakumar T, Frazier WA, Chapman WC.

Transplantation. 2014 Aug 27;98(4):394-401. doi: 10.1097/TP.0000000000000252.

7.

Imaging of CD47 expression in xenograft and allograft tumor models.

Zheleznyak A, Ikotun OF, Dimitry J, Frazier WA, Lapi SE.

Mol Imaging. 2013 Nov-Dec;12(8). doi: 10.2310/7290.2013.00069.

PMID:
24447619
8.

CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions.

Azcutia V, Routledge M, Williams MR, Newton G, Frazier WA, Manica A, Croce KJ, Parkos CA, Schmider AB, Turman MV, Soberman RJ, Luscinskas FW.

Mol Biol Cell. 2013 Nov;24(21):3358-68. doi: 10.1091/mbc.E13-01-0063. Epub 2013 Sep 4.

9.

Inhibitory signaling through signal regulatory protein-α is not sufficient to explain the antitumor activities of CD47 antibodies.

Soto-Pantoja DR, Miller TW, Frazier WA, Roberts DD.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2842; author reply E2844-5. doi: 10.1073/pnas.1205441109. Epub 2012 Aug 24. No abstract available.

10.

Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47.

Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, Dimitry J, Abu-Asab MS, Tsokos M, Roberts DD, Frazier WA.

Matrix Biol. 2011 Mar;30(2):154-61. doi: 10.1016/j.matbio.2010.12.004. Epub 2011 Jan 20.

11.

CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer.

Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ.

Nat Immunol. 2010 Feb;11(2):155-61. doi: 10.1038/ni.1836. Epub 2009 Dec 27.

12.

Decreased CD47 expression during spontaneous apoptosis targets neutrophils for phagocytosis by monocyte-derived macrophages.

Lawrence DW, King SB, Frazier WA, Koenig JM.

Early Hum Dev. 2009 Oct;85(10):659-63. doi: 10.1016/j.earlhumdev.2009.09.005. Epub 2009 Oct 7.

13.

Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress.

Isenberg JS, Qin Y, Maxhimer JB, Sipes JM, Despres D, Schnermann J, Frazier WA, Roberts DD.

Matrix Biol. 2009 Mar;28(2):110-9. doi: 10.1016/j.matbio.2009.01.002. Epub 2009 Jan 21.

14.

CD47 regulates bone mass and tumor metastasis to bone.

Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN.

Cancer Res. 2009 Apr 1;69(7):3196-204. doi: 10.1158/0008-5472.CAN-08-3358. Epub 2009 Mar 10.

15.

Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling.

Isenberg JS, Maxhimer JB, Powers P, Tsokos M, Frazier WA, Roberts DD.

Surgery. 2008 Nov;144(5):752-61. doi: 10.1016/j.surg.2008.07.009. Epub 2008 Sep 2.

16.

Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis.

Kohyama M, Ise W, Edelson BT, Wilker PR, Hildner K, Mejia C, Frazier WA, Murphy TL, Murphy KM.

Nature. 2009 Jan 15;457(7227):318-21. doi: 10.1038/nature07472. Epub 2008 Nov 26.

17.

Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses.

Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD.

J Biol Chem. 2009 Jan 9;284(2):1116-25. doi: 10.1074/jbc.M804860200. Epub 2008 Nov 11.

18.

Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.

Isenberg JS, Frazier WA, Krishna MC, Wink DA, Roberts DD.

Curr Drug Targets. 2008 Oct;9(10):833-41. Review.

19.

A naturally occurring extracellular alpha-beta clasp contributes to stabilization of beta3 integrins in a bent, resting conformation.

Vomund AN, Stuhlsatz-Krouper S, Dimitry J, Song Y, Frazier WA.

Biochemistry. 2008 Nov 4;47(44):11616-24. doi: 10.1021/bi8015108. Epub 2008 Oct 9.

PMID:
18841997
20.

Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease.

Isenberg JS, Romeo MJ, Maxhimer JB, Smedley J, Frazier WA, Roberts DD.

Ann Surg. 2008 May;247(5):860-8. doi: 10.1097/SLA.0b013e31816c4006.

21.

Thrombospondin-1: a physiological regulator of nitric oxide signaling.

Isenberg JS, Frazier WA, Roberts DD.

Cell Mol Life Sci. 2008 Mar;65(5):728-42. doi: 10.1007/s00018-007-7488-x. Review.

22.

CD47: a new target in cardiovascular therapy.

Isenberg JS, Roberts DD, Frazier WA.

Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):615-21. doi: 10.1161/ATVBAHA.107.158154. Epub 2008 Jan 10. Review.

23.

Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts.

Isenberg JS, Pappan LK, Romeo MJ, Abu-Asab M, Tsokos M, Wink DA, Frazier WA, Roberts DD.

Ann Surg. 2008 Jan;247(1):180-90.

24.

Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia.

Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, Roberts DD.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2582-8. Epub 2007 Oct 4.

PMID:
17916772
25.

Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.

Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD.

Blood. 2008 Jan 15;111(2):613-23. Epub 2007 Sep 21.

26.

Increasing survival of ischemic tissue by targeting CD47.

Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, Roberts DD.

Circ Res. 2007 Mar 16;100(5):712-20. Epub 2007 Feb 9.

PMID:
17293482
27.

CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1.

Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD.

J Biol Chem. 2006 Sep 8;281(36):26069-80. Epub 2006 Jul 11.

28.

Deficit of CD47 results in a defect of marginal zone dendritic cells, blunted immune response to particulate antigen and impairment of skin dendritic cell migration.

Hagnerud S, Manna PP, Cella M, Stenberg A, Frazier WA, Colonna M, Oldenborg PA.

J Immunol. 2006 May 15;176(10):5772-8.

29.

CD47 augments Fas/CD95-mediated apoptosis.

Manna PP, Dimitry J, Oldenborg PA, Frazier WA.

J Biol Chem. 2005 Aug 19;280(33):29637-44. Epub 2005 May 24.

30.

Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor.

Isenberg JS, Calzada MJ, Zhou L, Guo N, Lawler J, Wang XQ, Frazier WA, Roberts DD.

Matrix Biol. 2005 Apr;24(2):110-23. Epub 2005 Mar 17.

PMID:
15890262
31.

Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia.

Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA.

Blood. 2005 May 1;105(9):3577-82. Epub 2005 Jan 21.

32.

Cholesterol-independent interactions with CD47 enhance alphavbeta3 avidity.

McDonald JF, Zheleznyak A, Frazier WA.

J Biol Chem. 2004 Apr 23;279(17):17301-11. Epub 2004 Feb 13.

33.
34.

An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs.

McDonald JF, Dimitry JM, Frazier WA.

Biochemistry. 2003 Aug 26;42(33):10001-11.

PMID:
12924949
35.
36.

Integrin-associated protein (CD47) and its ligands.

Brown EJ, Frazier WA.

Trends Cell Biol. 2001 Mar;11(3):130-5. Review.

PMID:
11306274
37.

CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation.

Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, Lindberg FP, Vignery A.

J Biol Chem. 2000 Dec 1;275(48):37984-92.

39.

Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species.

Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL.

J Clin Invest. 2000 Apr;105(8):1095-108. Erratum in: J Clin Invest 2000 May;105(10):1483.

40.

Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia.

Sheibani N, Sorenson CM, Cornelius LA, Frazier WA.

Biochem Biophys Res Commun. 2000 Jan 7;267(1):257-61.

PMID:
10623607
42.

Vascular smooth muscle cell growth arrest on blockade of thrombospondin-1 requires p21(Cip1/WAF1).

Chen D, Guo K, Yang J, Frazier WA, Isner JM, Andrés V.

Am J Physiol. 1999 Sep;277(3):H1100-6. doi: 10.1152/ajpheart.1999.277.3.H1100.

43.

Antibody blockade of thrombospondin accelerates reendothelialization and reduces neointima formation in balloon-injured rat carotid artery.

Chen D, Asahara T, Krasinski K, Witzenbichler B, Yang J, Magner M, Kearney M, Frazier WA, Isner JM, Andrés V.

Circulation. 1999 Aug 24;100(8):849-54.

44.

Role of cholesterol in formation and function of a signaling complex involving alphavbeta3, integrin-associated protein (CD47), and heterotrimeric G proteins.

Green JM, Zheleznyak A, Chung J, Lindberg FP, Sarfati M, Frazier WA, Brown EJ.

J Cell Biol. 1999 Aug 9;146(3):673-82.

45.
46.

The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi.

Frazier WA, Gao AG, Dimitry J, Chung J, Brown EJ, Lindberg FP, Linder ME.

J Biol Chem. 1999 Mar 26;274(13):8554-60.

47.

Thrombospondin-1, PECAM-1, and regulation of angiogenesis.

Sheibani N, Frazier WA.

Histol Histopathol. 1999 Jan;14(1):285-94. doi: 10.14670/HH-14.285. Review.

PMID:
9987673
48.

Tissue specific expression of alternatively spliced murine PECAM-1 isoforms.

Sheibani N, Sorenson CM, Frazier WA.

Dev Dyn. 1999 Jan;214(1):44-54.

49.

Direct use of synthetic peptides for antiserum production.

Sheibani N, Frazier WA.

Biotechniques. 1998 Jul;25(1):28-30, 32. No abstract available.

Supplemental Content

Loading ...
Support Center